Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease

This study has been completed.
Information provided by:
Biogen Identifier:
First received: February 20, 2007
Last updated: July 10, 2009
Last verified: July 2009

The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is tolerated when given at different doses to patients with moderate to late-stage Parkinson's Disease who are also taking the Parkinson's medication, levodopa (L-DOPA).

This study will also explore:

  1. the pharmacokinetics of BIIB014 in Parkinson's patients who are also taking L-DOPA (this will be done by measuring the levels of BIIB014 in the blood at several different times during the study), and
  2. the activity of BIIB014 when given to Parkinson's patients who are also taking L-DOPA (this will be done by performing different Parkinson's Disease assessments during the study to examine change in waking OFF time, change in time with troublesome dyskinesia, change in Unified PD Rating Scale (UPDRS) scores, and Clinical Global Improvement).

Patients who enter this study will be randomly assigned to receive either BIIB014 or a placebo but because the study is blinded, neither they nor their study doctor will know which study treatment they are taking.

The study will be divided into 2 parts:

  • Part A: a, rapid, sequential cohort, dose escalation to establish MTD, followed by
  • Part B: a parallel-group exploration of the two highest tolerated doses versus placebo.

Note: As Part A of the study is now concluded, some of the study design information presented below (e.g., number of study arms) pertains only to Part B.

Condition Intervention Phase
Parkinson's Disease
Drug: BIIB014
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • Number and proportion of subjects with adverse events [ Time Frame: up to end of study ]
  • Assessment of clinical laboratory parameters [ Time Frame: up to end of study ]
  • Assessment of vital signs [ Time Frame: up to end of study ]
  • Assessment of ECG parameters. [ Time Frame: up to end of study ]

Secondary Outcome Measures:
  • Assess PK by measuring concentrations of BIIB014 and its N-acetyl metabolite in blood plasma. [ Time Frame: up to 24h following last dose (Part A only) ]
  • Explore activity of BIIB014 by evaluating standard Parkinson's disease assessments [ Time Frame: up to 8h following last dose (Part A); up to 24h following last dose (Part B only) ]

Enrollment: 83
Study Start Date: April 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
BIIB014 at MTD from Part A
Drug: BIIB014
oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
BIIB014 at dose immediately below MTD from Part A
Drug: BIIB014
oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
Placebo Comparator: 3 Drug: Placebo
Matched placebo for MTD or MTD-1


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must carry a diagnosis of idiopathic PD according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria, and be Hoehn & Yahr Stage II to IV (inclusive) when OFF.
  • Must be on a stable dose of L-3,4-dihydroxyphenylalanine (L-DOPA)/carbidopa or L-DOPA/benserazide for at least 4 weeks prior to enrollment.
  • Except for L-DOPA and certain allowed dopamine agonists, must not be receiving any other PD medications. (Current treatment with certain dopamine agonists is allowed but subjects must have been on a stable dose for at least 4 weeks prior to enrollment).
  • Some subjects must demonstrate a definite end of L-DOPA dose wearing off (at least 2 hours OFF time per waking day) and must be able to keep accurate patient diaries of PD activity.

Major Exclusion Criteria:

  • A Mini Mental State Examination (MMSE) score <26.
  • History or clinical features consistent with an atypical parkinsonian syndrome.
  • Any significant non-Parkinson's central nervous system disorder.
  • Any significant AXIS I psychiatric disease from the Diagnostic and Statistical Manual of Mental Disorders (DSM).
  • Any previous surgical intervention for Parkinson's Disease.
  • History of certain malignancies.
  • History of severe allergic anaphylactic reactions to any drug.
  • Clinically significant baseline electrocardiogram (ECG).
  • Orthostatic hypotension.
  • HbA1c >7.0%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00438607

Research Sites
Bangalore, India
Research Site
Chennai, India
Research Site
Hyderabaad, India
Research Site
Ludhiana, India
Research Site
Mumbai, India
Research Site
New Delhi, India
Research Site
Secunderabad, India
Research Site
Ashkelon, Israel
Research Site
Jerusalem, Israel
Research Site
Ramat-Gan, Israel
Research Site
Tel Aviv, Israel
United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Norwich, United Kingdom
Research Site
Salford, United Kingdom
Sponsors and Collaborators
Study Director: Biogen Idec Cambridge, MA USA
  More Information

Responsible Party: Biogen Idec MD, Biogen Idec Identifier: NCT00438607     History of Changes
Other Study ID Numbers: 204PD202
EUDRA CT NO: 2006-003490-27
ISCRTN 12870393
Study First Received: February 20, 2007
Last Updated: July 10, 2009

Keywords provided by Biogen:
Moderate to late stage Parkinson's Disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adenosine A2 Receptor Antagonists
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents processed this record on April 25, 2017